MTOR and breast cancer: In this work, we show that luminal breast cancer cells escape the antitumor activity of PI3Kα inhibition via CD44 abnormal splicing and that the subsequent increase in the CD44-HA interaction initiates Src-ERK signaling cascades, which maintained AKT and mTOR activities in the presence of PI3Kα inhibitor.